[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590545":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":39,"locations":47,"responsibleParty":64,"collaborators":66,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":25,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":25,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":50,"whyStopped":25,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketorolac Group","EXPERIMENTAL","patients in the experimental group will receive ketorolac treatment for Stanford Type A aortic dissection, consisting of a 60mg intramuscular injection preoperatively followed by 30mg twice daily for two days postoperatively, while maintaining standard baseline therapies including analgesia, blood pressure control, and subsequent cardiovascular surgical management.",[13],"Drug: Ketorolac",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","The control group will receive identical placebo treatment (normal saline) with the same dosage regimen, formulation, and timing of administration as the experimental group, while also continuing all standard baseline treatments and surgical interventions without modification. Both groups will follow identical protocols except for the active drug versus placebo",[19],"Drug: 0.9 % saline",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Ketorolac",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"0.9 % saline","0.9% saline",[15],[31,34,37],{"name":32,"affiliation":5,"role":33},"Tuo Pan, MD","STUDY_DIRECTOR",{"name":35,"affiliation":5,"role":36},"DongJin Wang, MD","STUDY_CHAIR",{"name":35,"affiliation":5,"role":38},"PRINCIPAL_INVESTIGATOR",[40,44],{"name":32,"role":41,"phone":42,"phoneExt":25,"email":43},"CONTACT","+8615205160210","pan_tuo@126.com",{"name":45,"role":41,"phone":25,"phoneExt":25,"email":46},"Dongjin Wang, MD","Dongjin_wang@126.com",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Nanjing Drum Tower Hospital","RECRUITING","Nanjing","Jiangsu","210008","China","CN",{"type":57,"coordinates":58},"Point",[59,60],118.77778,32.06167,{"lat":60,"lon":59},[63],{"name":32,"role":41,"phone":42,"phoneExt":25,"email":43},{"type":65,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[67,69,71,74,76,78,80,83],{"name":68,"class":6},"Guangdong Provincial People's Hospital",{"name":70,"class":6},"Huai'an First People's Hospital",{"name":72,"class":73},"Shandong Provincial Hospital","OTHER_GOV",{"name":75,"class":6},"First Affiliated Hospital of Harbin Medical University",{"name":77,"class":6},"The Second Affiliated Hospital of Harbin Medical University",{"name":79,"class":6},"The First Affilated Hospital of the Medical College, Shihezi University",{"name":81,"class":82},"Xinhua Hospital of Ili Kazak Autonomous Prefecture","UNKNOWN",{"name":84,"class":6},"Henan Provincial Chest Hospital","100590545","phase-3-study-on-ketorolac-for-improving-outcomes-and-prognosis-in-patients-with-stanford-type-a-aortic-dissection-100590545",false,"NCT06968806","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection -A Single-Center, Randomized, Double-Blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with Stanford Type A aortic dissection confirmed by imaging and scheduled for emergency surgery.\n\nAged between 18 and 65 years.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Patients who are unable to eat independently or require prolonged fasting.\n\nHistory of malignant tumors.\n\nBody weight \\\u003C50 kg.\n\nTraumatic aortic dissection.\n\nPatients with Marfan syndrome.\n\nUnstable vital signs requiring preoperative mechanical support or resuscitation (e.g., IABP \\[Intra-Aortic Balloon Pump\\], ECMO \\[Extracorporeal Membrane Oxygenation\\], LVAD \\[Left Ventricular Assist Device\\])\n\nPatients requiring preoperative endotracheal intubation.\n\nConsciousness impairment, central nervous system dysfunction, or evidence of cerebral malperfusion syndrome upon admission.\n\nPreoperative hematemesis, melena, fresh blood in stool, or symptoms of bowel dilation.\n\nClear evidence of limb malperfusion before surgery.\n\nPresence of organ malperfusion syndrome.\n\nPatients requiring interventional procedures to relieve organ malperfusion before surgery.\n\nHistory of gastrointestinal ulcers or chronic gastrointestinal inflammatory diseases.\n\nHistory of dialysis or renal insufficiency before admission.\n\nHistory of liver disease.\n\nAllergy to ketorolac tromethamine, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n\nChronic inflammatory diseases, autoimmune diseases, or long-term use of steroids or NSAIDs for other reasons.\n\nAbsence of cerebral perfusion during deep hypothermic circulatory arrest.\n\nHistory of major surgery or acute myocardial infarction within 90 days.\n\nHistory of cardiac or major vascular surgery.\n\nPregnant or lactating women.\n\nPatients who refuse to participate in this clinical trial or decline to sign the informed consent form.\n\nAny other conditions deemed unsuitable for participation by the investigator.","ALL","18 Years","65 Years",{"count":96,"type":97},360,"ESTIMATED","INTERVENTIONAL",[100],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly \\[IM\\] preoperatively and 30 mg twice daily \\[BID\\] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.",[103,104],"Aortic Dissection","Inflammation",[104,103,23],"2026-06-19",{"date":108,"type":109},"2026-06-23","ACTUAL",{"date":111,"type":109},"2025-10-27",{"date":113,"type":97},"2028-09-01",{"name":5,"class":6},1]